Search Results

Applied Science & Technology Full Text (H.W. Wilson)

Record details

Meta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry.

• Authors : Asiimwe IG; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.; Blockman M

Subjects: Warfarin*/Warfarin*/Warfarin*/administration & dosage ; Warfarin*/Warfarin*/Warfarin*/therapeutic use ; Genome-Wide Association Study*

• Source: Blood advances [Blood Adv] 2024 Oct 22; Vol. 8 (20), pp. 5248-5261.Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet

Record details

Randomized Comparison of Progression of Atherosclerotic Plaques and Calcification of Coronary Artery in Atrial Fibrillation Patients Treated With Edoxaban Versus Warfarin (The REPRESENT-AF trial).

• Authors : Ahn J; Division of Cardiology, Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea; Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.

Subjects: Atrial Fibrillation*/Atrial Fibrillation*/Atrial Fibrillation*/drug therapy ; Atrial Fibrillation*/Atrial Fibrillation*/Atrial Fibrillation*/complications ; Thiazoles*/Thiazoles*/Thiazoles*/therapeutic use

• Source: The American journal of cardiology [Am J Cardiol] 2024 Oct 15; Vol. 229, pp. 56-62. Date of Electronic Publication: 2024 Aug 08.Publisher: Excerpta Medica Country of Publication: United States NLM ID: 0207277 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Optimizing warfarin and dual oral anticoagulation practices in an academic clinic during a merger amid the COVID-19 pandemic in a marginalized population.

• Authors : Bahuva R; University at Buffalo, The State University of New York, Buffalo, NY, United States.; Jordan J

Subjects: Warfarin*/Warfarin*/Warfarin*/therapeutic use ; Warfarin*/Warfarin*/Warfarin*/administration & dosage ; Anticoagulants*/Anticoagulants*/Anticoagulants*/therapeutic use

• Source: International journal for quality in health care : journal of the International Society for Quality in Health Care [Int J Qual Health Care] 2024 Oct 03; Vol. 36 (3).Publisher: Oxford University Press Country of Publication: England NLM ID: 9434628 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Apixaban vs rivaroxaban vs warfarine : match à trois pour anticoaguler la FA chez le cirrhotique.

• Authors : Decker F; Avec la collaboration du groupe MIAjour, Service de médecine interne, Centre hospitalier universitaire vaudois, Lausanne.

Subjects: Rivaroxaban*/Rivaroxaban*/Rivaroxaban*/therapeutic use ; Rivaroxaban*/Rivaroxaban*/Rivaroxaban*/administration & dosage ; Warfarin*/Warfarin*/Warfarin*/therapeutic use

• Source: Revue medicale suisse [Rev Med Suisse] 2024 Oct 02; Vol. 20 (889), pp. 1787.Publisher: Médecine et Hygiène Country of Publication: Switzerland NLM ID: 101219148 Publication Model: Print Cited Medium: Print ISSN:

Record details

The Prevalent New-User Design to Study Drug-Drug Interactions: The Example of Sulfonylureas and Warfarin Interaction on the Risk of Severe Hypoglycemia.

• Authors : Wang W; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.; Cui Y

Subjects: Warfarin*/Warfarin*/Warfarin*/adverse effects ; Warfarin*/Warfarin*/Warfarin*/administration & dosage ; Sulfonylurea Compounds*/Sulfonylurea Compounds*/Sulfonylurea Compounds*/adverse effects

• Source: Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2024 Oct; Vol. 33 (10), pp. e70014.Publisher: Wiley Country of Publication: England NLM ID: 9208369 Publication Model: Print Cited Medium: Internet ISSN: 1099-1557 (Electronic)

Record details

Letter to the Editor Regarding "A Meta-Analysis of RCTs Comparing DOACs Against Warfarin for the Treatment of Left Ventricular Thrombus".

• Authors : Khalid S; Yorkshire Heart Centre, Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust, Leeds, UK.; Joseph T

Subjects: Warfarin*/Warfarin*/Warfarin*/therapeutic use ; Warfarin*/Warfarin*/Warfarin*/administration & dosage ; Thrombosis*/Thrombosis*/Thrombosis*/drug therapy

• Source: Heart, lung & circulation [Heart Lung Circ] 2024 Oct; Vol. 33 (10), pp. e53-e54.Publisher: Elsevier Australia Country of Publication: Australia NLM ID: 100963739 Publication Model: Print Cited Medium: Internet ISSN: 1444-2892

Record details

Peri-operative Anticoagulation Strategies, Bleeding and Thrombotic Complications in Pediatric Patients Undergoing Intervention for Congenital Portosystemic Shunts.

• Authors : Haimed A; Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA. Electronic address: .; Brandt KA

Subjects: Anticoagulants*/Anticoagulants*/Anticoagulants*/therapeutic use ; Anticoagulants*/Anticoagulants*/Anticoagulants*/administration & dosage ; Anticoagulants*/Anticoagulants*/Anticoagulants*/adverse effects

• Source: Journal of pediatric surgery [J Pediatr Surg] 2024 Oct; Vol. 59 (10), pp. 161609. Date of Electronic Publication: 2024 Jun 29.Publisher: Saunders Country of Publication: United States NLM ID: 0052631 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Comparing DOAC and warfarin outcomes in an obese population using the 'real-world' Michigan Anticoagulation Quality Improvement Initiative (MAQI 2 ) registry.

• Authors : Ardeshna N; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.; Current: Department of Cardiology, Rush University Medical Center, Chicago, IL, USA.

Subjects: Registries* ; Warfarin*/Warfarin*/Warfarin*/adverse effects ; Warfarin*/Warfarin*/Warfarin*/therapeutic use

• Source: Vascular medicine (London, England) [Vasc Med] 2024 Oct; Vol. 29 (5), pp. 543-552. Date of Electronic Publication: 2024 Aug 23.Publisher: SAGE Publications Country of Publication: England NLM ID: 9610930 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Nrf2 Ameliorates Atrial Fibrosis During Antithrombotic Therapy for Atrial Fibrillation by Modulating CYP2C9 Activity.

• Authors : Wu L; Medical Laboratory, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.; Li Z

Subjects: Atrial Fibrillation*/Atrial Fibrillation*/Atrial Fibrillation*/drug therapy ; Atrial Fibrillation*/Atrial Fibrillation*/Atrial Fibrillation*/enzymology ; Atrial Fibrillation*/Atrial Fibrillation*/Atrial Fibrillation*/prevention & control

• Source: Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 2024 Oct 01; Vol. 84 (4), pp. 440-450. Date of Electronic Publication: 2024 Oct 01.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 7902492 Publication Model: Electronic Cited Medium: Internet

Record details